- Home
- XBIO vs MBRX Comparison
XBIO vs MBRX Comparison
Compare XBIO & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIO
- MBRX
- Stock Information
- Founded
- XBIO N/A
- MBRX 2015
- Country
- XBIO United States
- MBRX United States
- Employees
- XBIO N/A
- MBRX N/A
- Industry
- XBIO Biotechnology: Pharmaceutical Preparations
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- XBIO Health Care
- MBRX Health Care
- Exchange
- XBIO Nasdaq
- MBRX Nasdaq
- Market Cap
- XBIO 6.3M
- MBRX 5.7M
- IPO Year
- XBIO N/A
- MBRX 2016
- Fundamental
- Price
- XBIO $4.24
- MBRX $1.88
- Analyst Decision
- XBIO Hold
- MBRX Strong Buy
- Analyst Count
- XBIO 1
- MBRX 2
- Target Price
- XBIO N/A
- MBRX $24.00
- AVG Volume (30 Days)
- XBIO 11.0K
- MBRX 62.3K
- Earning Date
- XBIO 11-12-2024
- MBRX 11-08-2024
- Dividend Yield
- XBIO N/A
- MBRX N/A
- EPS Growth
- XBIO N/A
- MBRX N/A
- EPS
- XBIO N/A
- MBRX N/A
- Revenue
- XBIO $2,523,427.00
- MBRX N/A
- Revenue This Year
- XBIO N/A
- MBRX N/A
- Revenue Next Year
- XBIO N/A
- MBRX N/A
- P/E Ratio
- XBIO N/A
- MBRX N/A
- Revenue Growth
- XBIO 7.15
- MBRX N/A
- 52 Week Low
- XBIO $2.78
- MBRX $0.40
- 52 Week High
- XBIO $5.20
- MBRX $6.24
- Technical
- Relative Strength Index (RSI)
- XBIO 53.05
- MBRX 47.84
- Support Level
- XBIO $3.93
- MBRX $1.65
- Resistance Level
- XBIO $4.32
- MBRX $1.99
- Average True Range (ATR)
- XBIO 0.25
- MBRX 0.20
- MACD
- XBIO 0.01
- MBRX 0.04
- Stochastic Oscillator
- XBIO 84.31
- MBRX 71.79
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.